Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Buspirone, first synthesized in 1968 and marketed in 1986, is a pharmacologically unique azapirone drug. It is effective for treating generalized anxiety, but not other anxiety disorders. Buspirone also is efficacious for depression, either alone or together with an antidepressant drug, and for treating adverse sexual effects. Studies of buspirone for substance use disorders have had disappointing outcomes, although it may be useful for treating coexisting anxiety and one controlled study suggested efficacy for heroin detoxification. Buspirone may be considered a treatment option for managing irritability, agitation, and aggression in older adult patients with dementia as well as in pediatric patients, although additional effectiveness studies are warranted. Buspirone and melatonin may synergistically promote neurogenesis, supporting the potential use of this combination for treating depression and cognitive impairment.

References 


Articles referenced by this article (22)


Show 10 more references (10 of 22)

Citations & impact 


Impact metrics

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/4733366
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/4733366

Article citations


Go to all (24) article citations

Other citations